Summary by Moomoo AI
Wuxi Pharmaceutical Ming Kand completed a share repurchase program on March 31, 2024, totaling 6,519,226 shares of A shares, representing 0.22% of the company's total share capital. The highest price of the repurchase operation was RMB58.66/share and the lowest price was RMB45.89/share, and the total used capital reached RMB331,114,239.93. The repurchase is a further move following the RMB 10 billion A share buyback completed on February 5, 2024 and aims to further preserve the company's value and shareholders' interests. Pursuant to the Board's resolution of March 8, the Company will continue to use its own funds to repurchase shares in a centralized competitive manner, and to divest all repurchased shares and reduce the registered capital. The Company undertakes to strictly comply with relevant laws and regulations and to fulfill its obligation to disclose information in a timely manner during the repurchase period.